Vir Biotechnology, Inc. Increase Decrease In Operating Lease Liability
Vir Biotechnology, Inc. (VIR) reported Increase Decrease In Operating Lease Liability of -$4.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-05
- Vir Biotechnology, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$2.31M.
- Vir Biotechnology, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$2.27M.
- Vir Biotechnology, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$2.32M.
- Vir Biotechnology, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$1.79M.
- Vir Biotechnology, Inc. increase decrease in operating lease liability for fiscal 2025 was -$7.37M.
- Vir Biotechnology, Inc. increase decrease in operating lease liability for fiscal 2024 was -$23.03M.
- Vir Biotechnology, Inc. increase decrease in operating lease liability for fiscal 2023 was -$13.05M.
- Vir Biotechnology, Inc. increase decrease in operating lease liability for fiscal 2022 was -$5.50M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$4.58M 10-Q · filed 2026-08-05 | -$6.90M derived: sum of 3 quarters · filed 2026-08-05 | -$8.69M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$2.27M 10-Q · filed 2026-05-07 | -$4.60M derived: sum of 2 quarters · filed 2026-05-07 | -$6.39M derived: sum of 3 quarters · filed 2026-05-07 | -$7.84M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$4.12M derived: sum of 2 quarters · filed 2026-02-23 | -$5.57M derived: sum of 3 quarters · filed 2026-08-05 | -$7.37M 10-K · filed 2026-02-23 |
| 2025-09-30 | -$1.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$3.25M derived: sum of 2 quarters · filed 2026-08-05 | -$5.04M 10-Q · filed 2025-11-05 | -$17.64M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$1.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$3.25M 10-Q · filed 2026-08-05 | -$15.85M derived: sum of 3 quarters · filed 2026-08-05 | -$18.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$1.80M 10-Q · filed 2026-05-07 | -$14.39M derived: sum of 2 quarters · filed 2026-05-07 | -$17.27M derived: sum of 3 quarters · filed 2026-05-07 | -$20.76M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$12.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$15.47M derived: sum of 2 quarters · filed 2026-02-23 | -$18.96M derived: sum of 3 quarters · filed 2026-02-23 | -$23.03M 10-K · filed 2026-02-23 |
| 2024-09-30 | -$2.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$6.37M derived: sum of 2 quarters · filed 2025-11-05 | -$10.43M 10-Q · filed 2025-11-05 | -$13.57M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | -$3.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$7.55M 10-Q · filed 2025-08-06 | -$10.69M derived: sum of 3 quarters · filed 2026-02-23 | -$14.37M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | -$4.07M 10-Q · filed 2025-05-08 | -$7.20M derived: sum of 2 quarters · filed 2026-02-23 | -$10.88M derived: sum of 3 quarters · filed 2026-02-23 | -$14.01M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | -$3.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$6.81M derived: sum of 2 quarters · filed 2026-02-23 | -$9.94M derived: sum of 3 quarters · filed 2026-02-23 | -$13.05M 10-K · filed 2026-02-23 |
| 2023-09-30 | -$3.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$6.80M derived: sum of 2 quarters · filed 2024-11-04 | -$9.91M 10-Q · filed 2024-11-04 | -$12.87M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$3.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$6.24M 10-Q · filed 2024-08-01 | -$9.19M derived: sum of 3 quarters · filed 2025-02-27 | -$10.72M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$3.10M 10-Q · filed 2024-05-03 | -$6.06M derived: sum of 2 quarters · filed 2025-02-27 | -$7.59M derived: sum of 3 quarters · filed 2025-02-27 | -$8.11M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$4.49M derived: sum of 2 quarters · filed 2025-02-27 | -$5.01M derived: sum of 3 quarters · filed 2025-02-27 | -$5.50M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$1.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$2.05M derived: sum of 2 quarters · filed 2023-11-03 | -$2.55M 10-Q · filed 2023-11-03 | -$2.70M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$519.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$1.01M 10-Q · filed 2023-08-04 | -$1.16M derived: sum of 3 quarters · filed 2024-02-26 | -$1.45M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$493.00K 10-Q · filed 2023-05-08 | -$645.00K derived: sum of 2 quarters · filed 2024-02-26 | -$935.00K derived: sum of 3 quarters · filed 2024-02-26 | -$1.03M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | -$152.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$442.00K derived: sum of 2 quarters · filed 2024-02-26 | -$539.00K derived: sum of 3 quarters · filed 2024-02-26 | -$535.00K 10-K · filed 2024-02-26 |
| 2021-09-30 | -$290.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$387.00K derived: sum of 2 quarters · filed 2022-11-03 | -$383.00K 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$97.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$93.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $4.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$3.68M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |